46 results about "Nedaplatin" patented technology

The invention relates to a composite developing thermosensitive gel embolizing agent as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly, preparing a mixed aqueous solution of an anticancer active substance, a thermosensitive material and a developing agent into composite developing thermosensitive gel; secondly, forming a composite developing thermosensitive gel embolizing agent by the composite developing thermosensitive gel and a coagulant on the scene, wherein the thermosensitive material is hydroxyl C1-4 alkyl cellulose, Pluronic, alginate or a mixture of the substances; the anticancer active substance is arsenic trioxide, docetaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, miriplatin, siRNA or a mixture of the substances; the developing agent is a water-soluble developing agent of iodixanol, ioversol or iohexol and the like. The preparation method disclosed by the invention is simple and convenient, is suitable for industrial large-scale production, is particularly suitable for preparing an embolizing agent which is biodegradable and good in biocompatibility and is used for hemorrhagic diseases, and is especially suitable for preparing the composite developing thermosensitive gel embolizing agent for treating liver cancer, kidney cancer, lung cancer, prostate cancer, uterine myoma or splenic tumor and the like.

Disclosed is a combination of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate (chemical name: 2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-[phenyl (benzoxy-L-alaninyl)]phosphate) (NUC-1031) and a platinum-based anticancer agent selected from carboplatin, dicycloplatin, oxaliplatin, satraplatin and nedaplatin. The combinations are useful in the treatment of cancer and particularly ovarian cancer.

The invention discloses a making method of naiad platinum with low-silver content, which comprises the following steps: reacting cis-platinum diiododiamide and silver nitrate with molar rate at 1: 2 for 3-8 h under 10-30 deg.c; filtering; adding halogenate MX [M is Na, K, Ca, Ba, NH4 or M is (CnH2n+1) 4N (n=1-4), X=Cl, Br, I] in the filtrate to remove trace silver; reacting for 0.5-1h under 10-30 deg.c; filtering; adding sodium glycolate in the solution; adjusting pH value to neutral to react for 3-10 h under 50-60 deg.c; decompressing; condensing; filtering; drying; obtaining the product; setting the molar rate of cis-platinum diiododiamide and sodium glycolate at 1: 1 and the molar rate of halogenate MX and silver nitrate at 0.1-0.01:1.

This invention relates to a preparation method of freeze-dried injection of nedaplatin.nedaplatin freeze-dried injection prepared with the inventive method can be used as therapeutic drug of cancer. The invention improves the stability of nedaplatin during lyophilization and shortens the period of lyophilization through adding ethanol during preparation process. the preparation method comprises adding water for injection 80% of nedaplatin into nedaplatin, stirring for dissolving, adding dextran, stirring for dissolving, determing the content of intermediate, adding ethanol 1-10% of the cumulative volume of the solution, adding water for injection to full dose, filtrating with 0.22 mu m millipore filter under aseptic condition, encapsulating in sirin bottle, plugging, freeze drying, rolling the opening, testing, and packaging. The optimum amount of ethanol is 1-5% of cumulative volume of the solution.

The invention relates to a method for detecting impurities in a freeze-dried powder injection of nedaplatin. In particular, the method comprises the following steps of: 1. adoption of a high performance liquid chromatography, wherein the chromatographic conditions are as follows: octyl chemically bonded silica is used as a bulking agent, a mobile phase is a mixture of water and acetonitrile or methanol, into which diethylamine or triethylamine is added, the detection wavelength is 205 to 222nm, the column temperature is between 20 and 45 DEG C, and the flow rate of the mobile phase is 0.5 to 2.0ml/min; 2. sample solution preparation, wherein the solution of the freeze-dried powder injection sample of nedaplatin, of which the nedaplatin content is 0.5 to 2mg/ml, is prepared by using a mixed solvent of water and methanol; and 3. measurement, wherein 5 to 20 micro liters of the sample solution is poured into a high performance liquid chromatograph, and chromatograms are recorded for analysis. By the method, the interference of skeleton excipient dextran with impurity detection is eliminated, and the impurities in nedaplatin raw materials can be easily, quickly and stably detected while the cost is lowered.

This invention relates purifing method a refined Nedaplatin. By weight proportion of 1:15 to 80, dissolve Nedaplatin crude product in water of 25 to 70 deg, after completeness dissolving add KI, by filtration, remove excessive Ag+, add 1 to 5 times volume C1 to C2 alkyl alcoho filtrate, through crystallization, cooling, filtration, dryness, gain Nedaplatin refiend product; the cooling crystallization temperature is -25 to 25deg, time for 5 to 30h,drying temperature is 40 to 70deg, and drying time is 4 to 15h. The Ag content of this refined Nedaplatin is very low.

The invention discloses a method for making antineoplastic medicine nedaplatin C2H8N2O3Pt. The method comprises the following technological processes that: cis-diiododiaminoplatinum (II) is taken as reactant; an amount of water is added in the reactant and is evenly stirred; then, argentum glycolate C2H3O3Ag and AgNO3 are slowly added in the solution with the molar ratio Pt (NH3) 2I2: C2H3O3Ag:AgNO3 equal to 1:1:1, and are reacted at a temperature of between 50 and 60 DEG C for 2 to 3 hours; after solid is filtered out, the filtrate is heated to 40 DEG C, and the pH value of the filtrate is adjusted to 7 by NaOH; the obtained solution is heated to 50 to 60 DEG C so as to carry out reaction for 4 hours; finally, the reaction liquid undergoes decompression condensation to obtain nedaplatin solid. The method has short process flow, high yield (above 56 percent) and high product purity.

The invention relates to a method for detecting impurities in nedaplatin. In particular, the method comprises the following steps of: 1. adoption of a high performance liquid chromatography, wherein the chromatographic conditions are as follows: octyl chemically bonded silica is used as a bulking agent, a mobile phase is a mixture of water and acetonitrile or methanol, into which diethylamine or triethylamine is added, the detection wavelength is 205 to 222nm, the column temperature is between 20 and 45 DEG C, and the flow rate of the mobile phase is 0.5 to 2.0ml/min; 2. sample solution preparation, wherein a solution of the sample, of which the nedaplatin content is 0.5 to 2mg/ml, is prepared by using the mobile phase, and the obtained solution is stored in a dark place at the temperature of between 2 and 8 DEG C; and 3. measurement, wherein 5 to 20 micro liters of the sample solution is poured into a high performance liquid chromatograph, and chromatograms are recorded for analysis. By the method, the impurities in nedaplatin raw materials can be easily, quickly and stably detected while the cost is lowered.

The invention provides a 5-fluorouracil-platinum (IV) complex, an intermediate, and a preparation method. The 5-fluorouracil-platinum (IV) complex is represented by a formula (1) shown in the description, wherein the part shown in the description is selected from cis-platinum, oxaliplatin, carboplatin, eptaplatin, nedaplatin or miriplatin, and is preferably the cis-platinum or the oxaliplatin; R1is -CnH2n-, n is an integer and is larger than or equal to 1, and preferably, -CnH2n- is a straight chain group; and R2 is -CmH2m+1, m is an integer and is larger than or equal to 1, and preferably, -CmH2m+1 is a straight chain group. According to the 5-fluorouracil-platinum (IV) complex provided by the invention, the toxic and side effects of the cis-platinum, the oxaliplatin and 5-fluorouracil can be reduced, and meanwhile, the 5-fluorouracil-platinum (IV) complex has a synergistic sensitization effect when being used in medicines for treating cancers and antitumor drugs.

An anticancer sustained-release gel injection sustained-release microspheres containing platinum-based compound, amphiphilic block copolymer, solvent and release regulator, the mixture of amphiphilic block copolymer and solvent has a temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The adjuvant in the sustained-release microspheres is poly(lactic acid)-glycollic acid copolymer; and the amphiphilic block copolymer is PLGA-PEG-PLGA copolymer. The preparation can be injected into artery, inside a tumor or around a tumor with remarkably reduced systemic toxicity of drug, and can be used for solid tumors at different stages. The platinum-based compound is selected from nedaplatin, carboplatin, cisplatin, enloplatin, ormaplatin, sulfato-1,2-diaminocyclohezane-platinum (SHP), picoplatin, cyclopentylamine platium, zeniplatin, spiroplatin, lobaplatin, iproplatin, oxaliplatin, cycloplatin, and dexormaplatin. The preparation can be used with radioactive particles and can enhance chemotherapy effect.

The invention relates to a method for preparing hydroxy carboxylic acid platinum complexes, in particular to a method for preparing platinum anticancer drugs of nedaplatin and lobaplatin. The preparation method includes that: compounds (I) and (II) and silver oxide in molar ratio of 1:1: 1, and certain quantity of water are added to a reactor and stirred to conduct light-shielding reaction for 1-20 hours at the temperature of 0-80 DEG C. The filtrate after filtration is concentrated to be dry, is cooled and rinsed by water, filtrated and rinsed by ethanol and is finally pumped out to obtain the product (III) after vacuum drying for 2-3 hours at the temperature of 40-45 DEG C. The invention obtains the product water solution through one-step reaction, concentrates the water solution to obtain the final product, has no need to adjust the pH value in the synthesis process, avoids the Na<+>, NO<3->, SO4<2->, Ba<2+> interference reaction, and accordingly realizes high productivity and good purity.

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

The invention belongs to the technical field of tumor treatment, and discloses application of a benzisoselenazole derivative combined with a platinum drug to the preparation of tumor treatment drugs and postoperative tumor recurrence drugs. The benziselenazole derivative has a structure as shown in the formula A, the platinum-based anticancer drug is selected from at least one of cisplatin, carboplatin, oxaliplatin, nedaplatin, and the like. The molar ratio of the benziselenazole derivative to the platinum-based anticancer drug is (1-99): (1-99). With the combination of the benzisoselenazole derivative and the platinum drug, the dosage of platinum-based anticancer drug with high toxicity can be effectively reduced and the safety of anticancer drugs can be improved; and Bel-7402 cell apoptosis can be induced by reducing Bcl-2/Bax protein expression ratio, and the expression of TrxR in tumor tissues can be synergistically inhibited, the proliferation rate of tumor cells after operation can be significantly reduced, and the growth inhibition rate of tumor cells after operation can be improved.

Disclosed is an anticancer slow release injection carrying both tumor drug resistance reversal agents and cytotoxic drugs, which comprises slow release micro-balloons and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer active ingredient is tumor drug resistance reversal agent selected from Pemetrexed, Raltitrexed, Nolatrexed, Nelarabine, Tipifarnib, Ronafarnib or Valspodar, and/or cytotoxic drugs selected from Eptaplatin, Nedaplatin, Melphalan, 4-hydroperoxycyclophosphamide, Vinorelbine, Tamoxifen, Tallimustine, Atrimustine, Semustine, Ranimustine, the slow release auxiliary materials are selected from poly(lactic acid), Polifeprosan, di-aliphatic acid and sebacylic acid copolymer, polyglycolic acid and glycolic acid copolymer, ethylene-vinylacetate copolymer and lactic acid polymer.

The invention discloses combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing an anti-tumor effect. The anti-tumor combined medicine comprises a cardiac glycosidecompound used as an active ingredient and a cytotoxic N-(2-hydroxypropyl) methacrylamide HPMA polymer medicine conjugate, wherein the cardiac glycoside compound is at least one of clinical medicine including digoxin, digitonin, deacetylated erioflorin, erioflorin C, G erioflorin, oleandrine and erioflorin K. The cytotoxic HPMA polymer medicine conjugate is an HPMA conjugate carrying at least oneof cis-platinum, carboplatin, nedaplatin, oxaliplatin, lerplatinum and heptplatinum. According to the invention, the cardiac glycoside compound and the N-(2-hydroxypropyl) methacrylamide HPMA polymermedicine conjugate are combined for use, so that the capability of causing anti-tumor immune response is improved, and the anti-tumor effect is enhanced.

The invention discloses an anticancer traditional Chinese medicine composition. The anticancer traditional Chinese medicine composition is prepared from 15-25 parts of platinum metal, 10-15 parts of taxol, 10-18 parts of gallium salt, 20-30 parts of coix seeds, 15-20 parts of salvia miltiorrhiza, 13-18 parts of evening primrose, 8-10 parts of camptothecin and 15-18 parts of lilac daphne flower buds. Nedaplatin is used as a material, the composition further effectively treat multiple cancers except reduction of the toxic and side effects, the Nedaplatin is matched with the taxol and the gallium salt in use, an anticancer effect is more obvious, natural lilac daphne flower bud extracting solution contains palmitic acid, oleic acid, linoleic acid, stearic acid, gamma-linolenic acid and trace elements including magnesium, zinc, copper, vitamins C, E, B6, B5 and the like, has a very good protection effect on a human body, enhances immunity, and the salvia miltiorrhiza and the camptothecin can improve the cancer cell inhibiting effect of drugs. The anticancer traditional Chinese medicine composition can effectively play a very good cancer cell growth inhibiting effect, can also improve the body's resistance and immunity, meanwhile has the very good therapeutic effect on multiple cancers and is wide in application range and convenient to popularize.

Anti-tumor platinum drug mineralized protein nanoparticles and a preparation method therefor are disclosed. The anti-tumor platinum-based drug mineralized protein nanoparticles include a platinum drug and a protein. The protein is one or more selected from the group consisting of albumin, transferrin, hemoglobin, and low-density lipoprotein. The platinum drug is cisplatin, iodoplatin, bromoplatin, oxaliplatin, carboplatin, or nedaplatin. A drug loading of the anti-tumor platinum-based drug mineralized protein nanoparticles is 1% to 50%.